Documents
Application Sponsors
Marketing Status
Application Products
001 | TABLET, FOR SUSPENSION; ORAL | EQ 60MG BASE; 5MG; 30MG | 0 | TRIUMEQ PD | ABACAVIR DOLUTEGRAVIR LAMIVUDINE |
FDA Submissions
TYPE 3; Type 3 - New Dosage Form | ORIG | 1 | AP | 2022-03-30 | PRIORITY |
Submissions Property Types
CDER Filings
VIIV HLTHCARE
cder:Array
(
[0] => Array
(
[ApplNo] => 215413
[companyName] => VIIV HLTHCARE
[docInserts] => ["Medication Guide","https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215413s000lbl.pdf#page=53"]
[products] => [{"drugName":"TRIUMEQ PD","activeIngredients":"ABACAVIR DOLUTEGRAVIR LAMIVUDINE","strength":"EQ 60MG BASE; 5MG; 30MG","dosageForm":"TABLET, FOR SUSPENSION; ORAL","marketingStatus":"Prescription","te":"None","rld":"No","rs":"No"}]
[labels] => [{"actionDate":"03\/30\/2022","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2022\\\/215413s000lbl.pdf\"}]","notes":""}]
[originalApprovals] => [{"actionDate":"03\/30\/2022","submission":"ORIG-1","actionType":"Approval","submissionClassification":"Type 3 - New Dosage Form","reviewPriority":"PRIORITY","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2022\\\/215413s000lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2022\\\/215413Orig1s000ltr.pdf\"}]","notes":">"}]
[supplements] =>
[actionDate] => 2022-03-30
)
)